Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Targeting survivin as a potential new treatment for chondrosarcoma of bone.

de Jong Y, van Oosterwijk JG, Kruisselbrink AB, Briaire-de Bruijn IH, Agrogiannis G, Baranski Z, Cleven AH, Cleton-Jansen AM, van de Water B, Danen EH, Bovée JV.

Oncogenesis. 2016 May 9;5:e222. doi: 10.1038/oncsis.2016.33.

2.

MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation.

Baranski Z, Booij TH, Kuijjer ML, de Jong Y, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC, Danen EH.

Genes Cancer. 2015 Nov;6(11-12):503-12.

3.

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.

Baranski Z, de Jong Y, Ilkova T, Peterse EF, Cleton-Jansen AM, van de Water B, Hogendoorn PC, Bovée JV, Danen EH.

Oncotarget. 2015 Nov 3;6(34):36113-25. doi: 10.18632/oncotarget.5333.

4.

Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.

Baranski Z, Booij TH, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC, Danen EH.

J Pathol. 2015 Jul;236(3):348-59. doi: 10.1002/path.4528. Epub 2015 Mar 30.

PMID:
25757065
5.

SYK is a candidate kinase target for the treatment of advanced prostate cancer.

Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM, Verhoef EI, Baranski Z, Xiong J, van de Water B, van der Pluijm G, Snaar-Jagalska BE, Danen EH.

Cancer Res. 2015 Jan 1;75(1):230-40. doi: 10.1158/0008-5472.CAN-14-0629. Epub 2014 Nov 11.

6.

Supplemental Content

Loading ...
Support Center